A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).

被引：2
|
作者：
Levy, Benjamin Philip
Giaccone, Giuseppe
Besse, Benjamin
Begic, Damir
Wu, Xiaoling
Fandi, Abderrahim
Paz-Ares, Luis
机构：
[1] Mt Sinai Hlth Syst, New York, NY USA
[2] Georgetown Univ, Washington, DC USA
[3] Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Celgene Corp, Summit, NJ USA
[5] Hosp Univ Virgen Rocio, Seville, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS9107
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9107
引用
收藏
页数：3
相关论文
共 50 条
  • [11] MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer (NSCLC)
    Scagliotti, G.
    Novello, S.
    Ramlau, R.
    Favaretto, A.
    Barlesi, F.
    Akerley, W.
    Von Pawel, J.
    Shuster, D.
    Schwartz, B.
    Sandler, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S798 - S799
  • [12] EFFICACY ANALYSIS FOR MOLECULAR SUBGROUPS IN MARQUEE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TIVANTINIB (ARQ 197) PLUS ERLOTINIB VERSUS PLACEBO PLUS ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Novello, Silvia
    Scagliotti, Giorgio
    Ramlau, Rodryg
    Favaretto, Adolfo
    Barlesi, Fabrice
    Akerley, Wallace
    Von Pawel, Joachim
    Orlov, Sergey
    Spigel, David R.
    Santoro, Armando
    Shepherd, Frances
    Hirsh, Vera
    Sequist, Lecia V.
    Shuster, Dale
    Zahir, Hamim
    Wang, Qiang
    Schwartz, Brian
    Von Roemeling, Reinhard
    Sandler, Allan B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S901 - S902
  • [13] Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008
    Gray, J. E.
    Owonikoko, T. K.
    Kato, T.
    Nadal, E.
    Greystoke, A.
    Cardona, A. F.
    Penrod, J.
    Wei, Z.
    Lara-Guerra, H.
    Schulz, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S896 - S896
  • [14] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) 1 chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes Castan, J.
    Guo, Z.
    Karantza, V.
    Aktan, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [15] Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer
    Scagliotti, Giorgio V.
    Novello, Silvia
    Schiller, Joan H.
    Hirsh, Vera
    Sequist, Lecia V.
    Soria, Jean-Charles
    von Pawel, Joachim
    Schwartz, Brian
    Von Roemeling, Reinhard
    Sandler, Alan B.
    CLINICAL LUNG CANCER, 2012, 13 (05) : 391 - 395
  • [16] Phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC): Final results
    Nin, R. Mesia
    Bossi, P.
    Hansen, A.
    Hsieh, C.
    Licitra, L. F.
    Tan, E. H.
    Chen, P.
    Miller, J.
    Siu, L. L.
    Haddad, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 382 - 382
  • [17] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Digumarti, Raghunadharao
    Wang, Yenyun
    Raman, Ganapathi
    Doval, Dinesh C.
    Advani, Suresh H.
    Julka, Pramod K.
    Parikh, Purvish M.
    Patil, Shekhar
    Nag, Shona
    Madhavan, Jayaprakash
    Bapna, Ajay
    Ranade, Annantbhushan A.
    Varadhachary, Atul
    Malik, Rajesh
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : 1098 - 1103
  • [18] Randomized, double-blind, placebo-controlled, phase III multicentre study of paclitaxel plus carboplatin (TC) versus TC plus endostar in patients with advanced non-small cell lung cancer (NSCLC)
    Han Baohui
    Xiu Qingyu
    Wang Huiming
    Luo Yi
    Bai Chunxue
    Guo Shuliang
    Liu Wenchao
    Zhuang Zhixiang
    Zhang Yang
    Zhou Jianying
    Jing Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S353 - S354
  • [19] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
    Gandhi, Leena
    Rodgriguez-Abreu, Delvys
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    De Angelis, Flavia
    Domine, Manuel
    Clingan, Philip
    Hochmair, Maximilian J.
    Powell, Steven
    Cheng, Susanna Yee-Shan
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Rubio-Viqueira, Belen
    Novello, Silvia
    Kurata, Takayasu
    Gray, Jhanelle E.
    Vida, John J.
    Wei, Ziwen
    Yang, Jing
    Raftopoulos, Harry
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2018, 78 (13)
  • [20] A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)
    Zhao, Hongyun
    Zhang, Zhonghan
    Luo, Fan
    Ma, Yuxiang
    Fang, Wenfeng
    Yang, Yunpeng
    Zhang, Yang
    Huang, Yan
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345